Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Confidentiality Slim, Punctuality Prime In Sunscreen TEA Draft Guidances

This article was originally published in The Tan Sheet

Executive Summary

CDER’s draft guidances on formatting TEAs, withdrawals of applications and requesting an advisory committee review arrive along with its draft on safety and effectiveness data to determine whether OTC sunscreen active ingredients should be added to the monograph.

You may also be interested in...



Sunscreen Guidances Underscore FDA Standards Aren’t Changing

CDER has published guidances, required by the 2014 Sunscreen Innovation Act, on FDA’s process for advisory committees to consider firms’ sunscreen ingredient proposals and on withdrawing pending proposals being considered by the agency.

Sunscreen Guidances Underscore FDA Standards Aren’t Changing

CDER has published guidances, required by the 2014 Sunscreen Innovation Act, on FDA’s process for advisory committees to consider firms’ sunscreen ingredient proposals and on withdrawing pending proposals being considered by the agency.

In Latest US OTC Switch, Ivermeticin 0.5% Lice Treatment Becomes Fully Nonprescription

FDA approved Arbor Pharmaceuticals' sNDA for an OTC switch of Sklice lice treatment. As it's been prescribed since its 2012 approval , Sklice will be available as a single-use lotion for topical treatment of head lice infestations in patients six months of age and older.

Topics

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel